Literature DB >> 12063640

Non-enzymatic glycation of IgG: an in vivo study.

Annunziata Lapolla1, R Tonani, D Fedele, M Garbeglio, A Senesi, R Seraglia, D Favretto, P Traldi.   

Abstract

The IgG glycation level of 30 healthy subjects and 60 type 2 diabetic patients with different degrees of metabolic control was evaluated by matrix-assisted laser desorption ionization mass spectrometry, a technique allowing the determination of mass increase of the IgG molecule. When applied to the digested mixture obtained by the action of papain on the plasma protein fraction, the same method established the mass increase of Fab and Fc fragments of IgG; for the former, a higher mass increase was found, possibly explained by its high reactivity to glucose. Experimental results were confirmed by molecular modeling calculations. Results suggest that the immunodeficiency observed in diabetic patients may be due to the inhibition of molecular recognition between antibody and antigen as a result of a change in functionality of the modified Fab fragment of IgG.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12063640     DOI: 10.1055/s-2002-32140

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  15 in total

Review 1.  Glycation of antibodies: Modification, methods and potential effects on biological functions.

Authors:  Bingchuan Wei; Kelsey Berning; Cynthia Quan; Yonghua Taylor Zhang
Journal:  MAbs       Date:  2017-03-08       Impact factor: 5.857

2.  Effect of Comorbid Diabetes on Clinical Characteristics of COVID-19 Patients Infected by the Wild-Type or Delta Variant of SARS-CoV-2.

Authors:  Jianguo Zhang; Jinhui Zhang; Zhimin Tao
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-04       Impact factor: 6.055

Review 3.  The outliers become a stampede as immunometabolism reaches a tipping point.

Authors:  Barbara S Nikolajczyk; Madhumita Jagannathan-Bogdan; Gerald V Denis
Journal:  Immunol Rev       Date:  2012-09       Impact factor: 12.988

4.  Reactive immunization suppresses advanced glycation and mitigates diabetic nephropathy.

Authors:  Tatiana Shcheglova; Sudesh Makker; Alfonso Tramontano
Journal:  J Am Soc Nephrol       Date:  2009-04-23       Impact factor: 10.121

5.  Covalent binding antibodies suppress advanced glycation: on the innate tier of adaptive immunity.

Authors:  T Shcheglova; S P Makker; A Tramontano
Journal:  Acta Naturae       Date:  2009-07       Impact factor: 1.845

Review 6.  Diabetes and sepsis: preclinical findings and clinical relevance.

Authors:  Philipp Schuetz; Pedro Castro; Nathan I Shapiro
Journal:  Diabetes Care       Date:  2011-03       Impact factor: 19.112

7.  Tuberculosis in poorly controlled type 2 diabetes: altered cytokine expression in peripheral white blood cells.

Authors:  Blanca I Restrepo; Susan P Fisher-Hoch; Paula A Pino; Adrian Salinas; Mohammad H Rahbar; Francisco Mora; Nicolas Cortes-Penfield; Joseph B McCormick
Journal:  Clin Infect Dis       Date:  2008-09-01       Impact factor: 20.999

8.  Quantitation and pharmacokinetic modeling of therapeutic antibody quality attributes in human studies.

Authors:  Yinyin Li; Michael Monine; Yu Huang; Patrick Swann; Ivan Nestorov; Yelena Lyubarskaya
Journal:  MAbs       Date:  2016-05-24       Impact factor: 5.857

9.  Assessing in vivo dynamics of multiple quality attributes from a therapeutic IgG4 monoclonal antibody circulating in cynomolgus monkey.

Authors:  Yinyin Li; Yu Huang; Janine Ferrant; Yelena Lyubarskaya; Yue Emma Zhang; Siyang Peter Li; Shiaw-Lin Billy Wu
Journal:  MAbs       Date:  2016-03-30       Impact factor: 5.857

10.  Resolving the micro-heterogeneity and structural integrity of monoclonal antibodies by hybrid mass spectrometric approaches.

Authors:  Yang Yang; Guanbo Wang; Ting Song; Carlito B Lebrilla; Albert J R Heck
Journal:  MAbs       Date:  2017-02-14       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.